Clinical trial · Interventional
Combination Therapy of Anthracyclines for Children With Nephroblastoma
A Multicenter, Randomized, Double-blind, Prospective Study to Evaluate the Efficacy and Safety of Vincristine, Dactinomycin/Cyclophosphamide Combination Therapy Combined With Liposomal Doxorubicin/Doxorubicin/Pharmorubicin/Pirarubicin in 0.5-14 Year Old Children With Nephroblastoma.
NCT03892330CI-TRIAL-00037816not yet recruitingPhase 4ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to estimate the efficacy and side effects of study drugs in children with nephroblastoma who are treated with combination therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| 0.5-14 Year Old Children With Nephroblastoma | Wilms Tumor | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (6)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Doxorubicin | Drug | Doxorubicin | ALIAS |
| Liposomal doxorubicin | Drug | — | UNRESOLVED |
| Oxytetracycline/ Cyclophosphamide | Drug | — | UNRESOLVED |
| Pharmorubicin | Drug | — | UNRESOLVED |
| Pirarubicin | Drug | — | UNRESOLVED |
| Vincristine | Drug | Vincristine | ALIAS |
Design
Arms and outcomes
Arms (4)
- type
- EXPERIMENTAL
- label
- liposomal doxorubicin
- description
- Drugs: liposome doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
- interventionNames
- Drug: Vincristine
- Drug: Oxytetracycline/ Cyclophosphamide
- Drug: Liposomal doxorubicin
- type
- ACTIVE_COMPARATOR
- label
- doxorubicin
- description
- Drug: doxorubicin Combination therapy: vincristine and dactinomycin or cyclophosphamide
- interventionNames
- Drug: Vincristine
- Drug: Oxytetracycline/ Cyclophosphamide
- Drug: Doxorubicin
- type
- ACTIVE_COMPARATOR
- label
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 6 Months
- Maximum age
- 14 Years
Show eligibility criteria text
Inclusion Criteria: 1. Age 6 months old to 14 years old. 2. No smoking history. 3. Pathologically confirmed nephroblastoma. 4. Informed consent and assent has been obtained before any study assessment is performed. 5. Good compliance. 6. Need to be applied to anthracycline chemotherapy according to the diagnosis and treatment recommendations for Chinese children with nephroblastoma (current version CCCG-WT-2016). 7. Need to be applied to doxorubicin according to the diagnosis and treatment recommendations for children with nephroblastoma (CCCG-WT-2016). Exclusion Criteria: 1. Patients with cardiovascular disease in addition to nephroblastoma. 2. Patients with digestive, neurological, circulatory, renal or liver disease, blood disorders or growth abnormalities unrelated to the tumor. 3. Patients have been treated with chemotherapy or cardiotoxic nephrotoxic drugs in the past 4 weeks. 4. Patients have participated in other clinical trials in the past 4 weeks. 5. Patients with mediastinal disease. 6. Patients who have undergone mediastinal radiotherapy due to other tumors or received other treatments that may cause heart damage.
References
Publications (0)
Data not yet available
No reference posted for this study.